PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Olmesartan and Aliskiren Interaction

Drug interaction information between Olmesartan and Aliskiren.

Olmesartan and Aliskiren have a documented major interaction in FDA labeling.

FDA drug labeling documents a major-severity interaction between Olmesartan and Aliskiren. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.

Drug A

Olmesartan

Angiotensin II Receptor Blocker (ARB)

Drug B

Aliskiren

Direct Renin Inhibitor

How They Interact

Both drugs block the same system that controls blood pressure, which can put too much strain on your kidneys. This increases the risk of dangerously low blood pressure and high potassium levels.

What To Do

Avoid using these medicines together, especially if you have diabetes or kidney disease. Your doctor will need to check your blood and kidney health often.

FDA Label Information

7.4 Dual Blockade of the Renin Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Do not co-administer aliskiren with olmesartan medoxomil and hydrochlorothiazide in patients with diabetes [see Contraindications (4) ]. Avoid use of aliskiren with olmesartan medoxomil and hydrochlorothiazide in patients with renal impairment (GFR <60 ml/min).

Frequently Asked Questions

Can I take Olmesartan and Aliskiren together?

This is a major interaction. Avoid using these medicines together, especially if you have diabetes or kidney disease. Your doctor will need to check your blood and kidney health often.

How serious is the interaction between Olmesartan and Aliskiren?

This interaction is classified as "major" severity by the FDA. Major interactions may be life-threatening or cause serious side effects.

Why do Olmesartan and Aliskiren interact?

Both drugs block the same system that controls blood pressure, which can put too much strain on your kidneys. This increases the risk of dangerously low blood pressure and high potassium levels.

Understanding the Olmesartan and Aliskiren Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Olmesartan belongs to the Angiotensin II Receptor Blocker (ARB) class and Aliskiren belongs to the Direct Renin Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Both drugs block the same system that controls blood pressure, which can put too much strain on your kidneys. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Olmesartan has 7 total documented interactions on file in this dataset, and Aliskiren has 28. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Avoid using these medicines together, especially if you have diabetes or kidney disease. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Olmesartan or Aliskiren based on a web page, speak with your prescriber or pharmacist before making any change.

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.